Dr. Martens (CHIX:DOCSL) EBIT: £59.3 Mil (TTM As of Mar. 2026)


CHIX:DOCSL Dr. Martens PLC CHIX:DOCSL
52 GF Score
Price £0.70
GF Value £0.72
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Dr. Martens EBIT?

Dr. Martens CHIX:DOCSL +1.30% 52 EBIT is £59.3 Mil as of Mar. 2026. GuruFocus rates CHIX:DOCSL with a GF Score™ of 52/100 and a GF Value™ of £0.72 (Fairly Valued). The stock has 3 warning signs investors should review.

Dr. Martens's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was £56.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was £59.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dr. Martens's annualized ROC % for the quarter that ended in Mar. 2026 was 13.85%. Dr. Martens's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 35.50%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dr. Martens's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 6.70%.

Dr. Martens  (CHIX:DOCSl) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dr. Martens's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=114.8 * ( 1 - 22.65% )/( (638.9 + 643.7)/ 2 )
=88.7978/641.3
=13.85 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=865.4 - 130.8 - ( 95.7 - max(0, 182 - 396.8+95.7))
=638.9

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=877.3 - 53.3 - ( 180.3 - max(0, 159.9 - 417.1+180.3))
=643.7

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Dr. Martens's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=113.6/( ( (181.6 + max(168.7, 0)) + (174.8 + max(114.9, 0)) )/ 2 )
=113.6/( ( 350.3 + 289.7 )/ 2 )
=113.6/320
=35.50 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(94.7 + 199.8 + 6.6) - (130.8 + 0 + 1.6)
=168.7

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(56 + 160.8 + 11.8) - (53.3 + 0 + 60.4)
=114.9

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dr. Martens's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=59.3/885.075
=6.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr. Martens EBIT Related Terms

Dr. Martens EBIT Historical Data

* Premium members only.

The historical data trend for Dr. Martens's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr. Martens EBIT Chart

Dr. Martens Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only 228.20 176.90 124.00 38.00 59.30

Dr. Martens Semi-Annual Data
Mar18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 82.60 -14.00 52.00 2.50 56.80

CHIX:DOCSL vs NKE, DECK, ONON: EBIT Comparison

For the Footwear & Accessories subindustry, Dr. Martens's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr. Martens EV-to-EBIT vs Manufacturing - Apparel & Accessories Industry

For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, Dr. Martens's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dr. Martens's EV-to-EBIT falls into.


CHIX:DOCSL
52GF Score
Dr. Martens PLC CHIX:DOCSL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr. Martens EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was £59.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of £59.3 Mil mean?
Dr. Martens (CHIX:DOCSL) has a EBIT of £59.3 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dr. Martens.
Is Dr. Martens' EBIT too high?
Dr. Martens' current EBIT is £59.3 Mil. Overall, Dr. Martens has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr. Martens' EBIT compare to NKE and DECK?
Dr. Martens' EBIT of £59.3 Mil can be compared against companies in the Manufacturing - Apparel & Accessories industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Manufacturing - Apparel & Accessories company?
A good EBIT depends on the Manufacturing - Apparel & Accessories industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dr. Martens. Dr. Martens's current EBIT is £59.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Martens stock overvalued right now?
Based on GuruFocus' analysis, Dr. Martens (CHIX:DOCSL) is currently considered Fairly Valued. The stock's GF Value™ is £0.72, compared to a current price of £0.70 — trading 2.5% below its estimated fair value. The current EBIT is £59.3 Mil. Dr. Martens' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dr. Martens (CHIX:DOCSL), the current EBIT is £59.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr. Martens (CHIX:DOCSL) Overvalued in 2026?

Based on GuruFocus' analysis, Dr. Martens stock appears to be undervalued. The current stock price of £0.70 is trading 2.5% below its estimated GF Value™ of £0.72. GuruFocus considers Dr. Martens to be Fairly Valued.

Key valuation signals for CHIX:DOCSL:

  • EBIT: £59.3 Mil
  • GF Value™: £0.72 vs. price of £0.70 (2.5% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the CHIX:DOCSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr. Martens Business Description

Address 28 Jamestown Road, Camden, London, GBR, NW1 7BY
Dr. Martens PLC is engaged in the footwear business. Its product segments include Originals, Fusion, Kids and Casual, and a complementary range of Accessories. The company has sales through E-commerce, Retail, and Wholesale of Products. Geographically, it derives the majority of its revenue from EMEA and has a presence in the Americas and APAC.
52GF Score

Get the complete analysis for CHIX:DOCSL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.70
Price
£0.72
GF Value